Where does the original research drug go?

In the national drug procurement, domestic generic drug companies have become the main bidders.

What will happen to the original research drug after the standard has passed, the choice of each pharmaceutical company is not the same.

01 Collection of original research drugs with different "destinies"

Recently, Shanghai Roche Pharmaceuticals Co.

Capecitabine tablets are one of the third batch of nationally sourced varieties.

At present, the fourth batch of national drug procurement has been carried out, and the fifth batch is coming soon.

It is worth noting that in 2019 and 2020, Astellas has also successively sold its tamsulosin hydrochloride sustained-release capsules (trade name: Haro) and febuxostat tablets (trade name: febrix).

Coincidentally, not long ago, Eli Lilly China announced internal adjustments to the sales and regional marketing team of Enpagliflozin (trade name: Ou Tangjing), as well as duloxetine hydrochloride (trade name: Xinbaida) and tadala.

According to reports, Eli Lilly's Diabetes Products Division also welcomed a new vice president.

Lilly's adjusted product line includes many products that have entered the collection, such as Ou Tangjing and Xialli.

Recently, Daiichi Sankyo also announced plans to merge cardiovascular, anti-infection, and respiratory analgesia lines.

In response to changes in market competition, Bristol-Myers Squibb has adopted a more "relentless" strategy in related products.

02Prepare for a rainy day, intensive adjustment of MNC mature product line

Even for non-centralized products, in the face of changes in the Chinese pharmaceutical market, multinational pharmaceutical companies have begun to take the lead in making choices, transferring promotion rights, merging product lines, layoffs.

Erlotinib hydrochloride tablets were once a star product of Roche.

After comprehensive consideration, Roche also gradually stopped the marketing of its antibiotic drug Rochephene this year; and not long ago, Eli Lilly and 3SBio and its subsidiaries formally stopped cooperating to promote humerin series products and humerin.

At the same time, another trend is also emerging.

In addition, according to Sina Pharmaceuticals, Roche is also shifting the general medicine and specialty medicine division from its previous business model based on product lines (such as Xiaoxi, Yamei Luo, Luo Gaiquan, etc.

However, the promotion case of the combined product line has not been smooth.
At the end of 2020, Eli Lilly will set up a CCO hybrid team for the three products of Xinbaida, Cially, and Futai for the smooth transition of the business and the exploration of uncertainty.
Later, based on this year's business plan and the clarification of internal and external changes in the product, the CCO hybrid team was cancelled.

The continuous deepening of my country's pharmaceutical reform is bringing profound changes to the pharmaceutical market.
On the one hand, the state encourages pharmaceutical innovation and accelerates the approval and listing of new drugs; on the other hand, the state hopes to effectively reduce the proportion of medicines in medical expenditures through medical insurance negotiations, mass purchases, and regulation of pharmaceutical sales.

It can be seen that the traditional business model is difficult to adapt to the current Chinese pharmaceutical market environment.
After the implementation of a series of pharmaceutical policies, multinational pharmaceutical companies have gradually begun to transform their drug development and promotion and sales strategies in China, and at the same time they have increased their investment in innovative drug development.
Pharmaceutical companies are eagerly seeking internal and external strategic transformation.